Abstract
We evaluated the clinical effect of several doses of the 21-aminosteroid U74006F in acute experimental autoimmune encephalomyelitis (EAE) and compared it with the administration of methylprednisolone (MP). There was no significant change in the clinical course of EAE with the dosages we used, whereas the effect of MP was unquestionably beneficial. Based on these results U74006F does not seem to be a promising drug for the treatment of exacerbations of multiple sclerosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
